

# WUOF 2017

agenda

October 19, 2017  
Centro de Congressos de Lisboa  
Praça das Indústrias  
1300-307 Lisboa, Portugal

World Urological  
Oncology Federation



Conference Co-Chairs:

Laurence Klotz, MD  
WUOF Chairman  
(Canada)

Nathan Lawrentschuk, MD  
(Australia)



+351 218921400

[www.wuof.org](http://www.wuof.org)

## INTERNATIONAL ISSUES IN UROLOGIC ONCOLOGY

Conference Co-Chairs | Nathan Lawrentschuk, MD and Laurence Klotz, MD

ROOM AUDITORIUM VII

WELCOME & INTRODUCTIONS

- 7:00 Meet and Greet International Colleagues (coffee and refreshments served)
- 7:30 **Co-Chairmen's Welcome & Framing of Theme** | Laurence Klotz & Nathan Lawrentschuk
- 7:35-8:45 **SESSION ONE | PROSTATE CANCER-LOCALIZED** | Co-Moderators: Mark Frydenberg & Francisco Botelho
- 1 **The USPSTF Screening Review—What are the Implications?** | Matthew Cooperberg, MD
  - 2 **Focal Therapy for Prostate Cancer - Who and How?** | Rafael Sanchez-Salas, MD
  - 3 **Active Surveillance: Biopsy vs MRI for Follow Up** | Arnauld Villers, MD
  - 4 **Advanced Risk Modeling for Prostate Cancer** | Boris Hadaschik, MD
  - 5 **DNA Repair Mutations and Prostate Cancer** | Marc Dall'Era, MD
  - 6 **DISCUSSION**
- 8:50-9:50 **SESSION TWO | KIDNEY CANCER** | Co-Moderators: Arnaldo Figueiredo & Peter Mulders
- 7 **Renal Tumor Anatomic Complexity: Clinical Implications for Urologists** | Robert Uzzo, MD
  - 8 **Management of Complex Renal Masses: Risk Benefit Trade-Off of Partial vs Radical Nephrectomy** | Alessandro Volpe, MD
  - 9 **Cytoreductive Surgery for RCC** | Makarand Khochikar, MD
  - 10 **Variation in Surgical Quality Affects Outcome of RCC Treatment** | Antonio Finelli, MD
  - 11 **DISCUSSION**
- 9:50-11:00 **SESSION THREE | PROSTATE CANCER: ADVANCED** | Co-Moderators: Nathan Lawrentschuk & Fernando M Calais da Silva
- 12 **Prostate Cancer Stem Cells** | Ricardo Leão, MD
  - 13 **Local Treatment for Metastatic Prostate Cancer** | Derya Tilki, MD
  - 14 **CV Disease and ADT** | Jehonathan Pinthus, MD
  - 15 **Bone Targeted Treatment in Advanced Prostate Cancer** | Fred Saad, MD
  - 16 **Radiogenomics, MRI & Prostate Cancer Imaging** | Robert Reiter, MD
  - 17 **DISCUSSION**
- 11:00-11:45 **SESSION FOUR | BLADDER CANCER** | Co-Moderators: Peter Black & Badrinath Konety
- 18 **Translational Observations from Mutation Profiling of Muscle Invasive Bladder Cancer** | Seth Lerner, MD
  - 19 **Neoadjuvant Chemo - When, What and Why?** | Badrinath Konety, MD
  - 20 **Can Genetic Analysis in Bladder Cancer Enhance Decision Making?** | Peter Black, MD
  - 21 **DISCUSSION**
- 11:45 **WORKING LUNCH**  
Complimentary to All Seated Participants Attending Session Four Working Lunch
- 12:00-12:45 **SESSION FIVE | MAJOR OBSERVATIONS** | Co-Moderators | Laurence Klotz, Peter Hammerer
- 22 **Observation #1 | Prostate-Specific Membrane Antigen-Radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer** | Markus Graefen, MD
  - 23 **Observation #2 | Oligometastatic Bone Disease in Prostate Cancer Patients Treated on the TROG 03.04 RADAR Trial** | Shin Egawa, MD
  - 24 **Observation #3 | The Unmet Need in Locally Advanced RCC Treatment: Game Changers?** | Peter Mulders, MD
  - 25 **DISCUSSION**
- 12:45 ADJOURN

